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Background: The diagnosis of chronic obstructive pulmonary disease (COPD) is based on airflow obstruction. In
epidemiological studies, spirometric data have often been lacking and researchers have had to rely almost solely on
questionnaire answers. The aim of this study is to assess the diagnostic accuracy of questionnaire answers to detect
COPD.
Methods: A sample of the Swedish general population without physician-diagnosed asthma was randomly selected
and interviewed using a respiratory questionnaire. All eligible subjects aged 25–75 years (n = 3892) performed
spirometry for detection of airflow obstruction using Global Initiative for Chronic Obstructive Lung Disease (GOLD) or
American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria. Sensitivity, specificity, positive likelihood
ratio (LR+), positive predictive values (PPVs), and negative predictive values (NPVs) were calculated to define diagnostic
accuracy of questionnaire answers.
Results: The sensitivity of the question “Have you been diagnosed by a physician as having COPD or emphysema?” in
detecting airflow obstruction was 5.7% using GOLD, and 9.8% using ATS/ERS, criteria; specificity was 99.7% for GOLD
and 99.5% for ATS/ERS. Sensitivity, specificity, and PPV were higher for the question compared to self-reported symptoms
of chronic bronchitis in identifying subjects with airflow obstruction.
Conclusions: The high specificity and good PPV suggest that the question “Have you been diagnosed by a physician as
having COPD or emphysema?” is more likely to identify those who do not have airflow obstruction, whereas the low
sensitivity of this question could underestimate the real burden of COPD in the general population.
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Chronic obstructive lung disease (COPD) continues to
be an important source of morbidity and mortality and a
socioeconomic burden worldwide despite the attention
paid by the scientific community and the availability of
guidelines and recommendations on prevention, diagno-
sis, and treatment [1,2]. Unfortunately, there is still no
consensus on the criteria for diagnosis of COPD. None-
theless, airflow obstruction is commonly recognized as
a key feature of COPD, and spirometry is the routine* Correspondence: nicola.murgia@unipg.it
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reproduction in any medium, provided the orprocedure of choice for detecting airflow obstruction
and diagnosis of COPD [2,3].
The degree of airway obstruction that characterizes
COPD is still under discussion since the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) has pro-
posed a fixed post-bronchodilator ratio of forced expira-
tory volume in 1 second (FEV1) to forced vital capacity
(FVC) of <0.70 [4] as its criterion. This is widely applied,
also for its practicability, but has been criticized for the
risk of overdiagnosis [5]. Other authors, on behalf of the
American Thoracic Society (ATS) and the European
Respiratory Society (ERS), have defined airway obstruction
as a reduction in FEV1/FVC below the age-, gender-, and
race-adjusted fifth percentile of a healthy, never-smoking
population, which is regarded as the lower limit of normalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the risk of overdiagnosing the disease, especially in elderly
subjects [7].
According to the GOLD definition, even if dyspnoea,
chronic cough, and chronic sputum production are often
associated with COPD, the definition of COPD does not
include the terms “chronic bronchitis” or “emphysema”
[2,4]. In epidemiological studies, especially in follow-up,
questionnaire-based surveys, or in large, population-
based investigations, spirometric data are often lacking
and researchers have to rely almost solely on subjects’
answers. As the questions were originally designed for
detecting asthma [8,9], validity of questionnaires in de-
tecting COPD needs to be checked against a diagnostic
gold standard for the disease. Although agreement still
needs to be reached on a definition of airway obstruction
criteria for COPD, some researchers have tried to valid-
ate specific questionnaires based on symptoms and other
variables in high risk populations (smokers). They found
that an association of several questions, coupled with a
scoring system, could yield reasonable sensitivity and
specificity to detect airflow obstruction in these high risk
groups [10,11]. In another study, out of a small sample
of nurses reporting physician-diagnosed COPD, 27% had
airflow obstruction [12].
The objective of this study is to assess, in a large sample
of the general population, the validity of questionnaire an-
swers to detect COPD, compared to current definitions of
COPD, based on airflow obstruction.
Methods
Population and questionnaire
A general population sample of 6685 men and women
25–75 years old was randomly selected from the popula-
tion register in Göteborg, Sweden, and sent a postal
questionnaire and an invitation to undergo a clinical
examination, as previously described [13,14]. The study
population was recruited in 2001. The key question
about physician-diagnosed COPD was introduced in
2004 and the present study was completed in 2008.
Altogether 4520 men and women answered the ques-
tionnaire. An affirmative answer to the question “Have
you been diagnosed by a physician as having COPD or
emphysema?” defines the doctor-diagnosed COPD cat-
egory. Respondents reporting cough and phlegm for at
least 3 months within 1 year for 2 consecutive years fell
into the chronic bronchitis category. The questionnaire
also included questions about age, sex, height, weight,
smoking habits, current respiratory therapy, respiratory
symptoms, respiratory infections in the last year, and the
question “Have you been diagnosed by a physician as
having asthma?” Respondents (n = 315) with physician-
diagnosed asthma were excluded, as well the 21 respon-
dents not answering the question regarding asthma.Another 292 respondents were excluded due to missing
information about spirometry and smoking habits,
yielding a final number of 3892 study subjects. The study
was approved by the Ethical Committee of Göteborg
University (No. 237/2000) and all subjects gave their in-
formed consent.
Spirometry
Before the spirometry, subjects were weighed and height
was measured with subjects barefoot and wearing light
clothes. Spirometry was performed with a dry wedge
spirometer (Vitalograph; Buckingham, UK). Forced ex-
piratory volume in 1 second and FVC were expressed
in liters. Percentages of predicted values of lung func-
tion variables (i.e., FEV1, and FEV1/FVC ratio) were
calculated using the European Community for Steel
and Coal (ECSC)/ERS equation [15]. No broncho-
reversibility test with short-acting bronchodilators was
performed. A FEV1/FVC ratio <0.7 indicates airway ob-
struction according to GOLD criteria [4,16] and a FEV1/
FVC <1.645 × residual standard deviation (RSD) below
the predicted value was used as estimation of the LLN,
which is the criterion used by the ATS/ERS for defining
airway obstruction [6,15].
Statistical analysis
Continuous data are expressed as mean ± standard devi-
ation (SD), whereas categorical data are presented as
numbers and percentages. We used sensitivity, specifi-
city, positive likelihood ratio (LR+), positive predictive
values (PPVs), and negative predictive values (NPVs) to
define the diagnostic accuracy of the questions, indicat-
ing self-reported, physician-diagnosed COPD and calcu-
lated for each COPD definition (GOLD and LLN-based)
with 95% confidence intervals (CIs). We also assessed
accuracy parameters in a sample of the population
aged >40 years, in subjects not reporting wheezing, and
in subcategories by gender and smoking habits (never-
smokers, former smokers, current smokers). All calcula-
tions were performed with SPSS 18.0 (IBM Corp., New
York, NY, USA) and Simple Interactive Statistical Analysis
(SISA) free software [17].
Results
In the whole study population, 366 subjects (9.4%) had
COPD according to the GOLD criteria, whereas 163
(4.2%) had COPD according to LLN criteria (Table 1).
Altogether 33 subjects (0.8%) reported doctor-diagnosed
COPD, in 19 of whom (57.6%) the diagnosis was made
after 2001. Ninety subjects (2.3%) were classified as
having chronic bronchitis. Other characteristics of the
study population, stratified for COPD diagnosis, are
displayed in Table 1. Sensitivity, specificity, LR+, PPVs,
and NPVs in the overall population can be seen in Table 2















Women,% 49.2 66.9 52.5
Age (mean ± SD), yrs 58.3 ± 9.5 54.9 ± 10.3 51.7 ± 10.6
BMI (mean ± SD),
kg/m2
25.6 ± 3.9 25 ± 3.8 26.1 ± 4
Spirometry
FEV1 (L) (mean ± SD) 2.7 ± 0.8 2.5 ± 0.8 3.3 ± 0.8
FEV1% (mean ± SD) 65.1 ± 5.3 61.9 ± 6.3 78.0 ± 6.3
FEV1/FVC (mean ± SD) 64.9 ± 5.3 61.7 ± 6.3 77.9 ± 6.4
Dyspnea,% 6.3 9.2 6.3





Never-smokers,% 29.8 27.6 47.7
Former smokers,% 38.8 35.6 36.2




22.6 ± 15.5 22.2 ± 13.8 15 ± 12.2
*In the whole study population, 366 subjects (9.4%) had COPD according to
the GOLD criteria; 163 (4.2%) had COPD according to LLN criteria.
ATS = American Thoracic Society; BMI = body mass index; COPD = chronic
obstructive pulmonary disease; ERS = European Respiratory Society; FEV1 = forced
expiratory volume in 1 second; FEV1%=% of FEV1 compared to the predicted
value; FEV1/FVC = FEV1/forced vital capacity ratio; GOLD =Global Initiative for
Chronic Obstructive Lung Disease; SD = standard deviation.
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been diagnosed by a physician as having COPD or em-
physema?” in detecting airflow obstruction was 5.7%
using the GOLD definition and 9.8% using the ATS/ERS
definition, whereas specificity was high for both defini-
tions, 99.7% for GOLD and 99.5% for ATS/ERS. Sensitiv-
ity, specificity, and PPV for the above question were
higher than the self-reported symptoms of chronic bron-
chitis in identifying subjects with COPD for both airway
obstruction definitions (GOLD and LLN). We performed
the analysis in individuals >40 years old and in those who
did not report wheezing, but the results were similar
(data not shown). In Table 3, we report diagnostic accur-
acy data for women and men (see Table 3 file). Tables 4
and 5 describe accuracy data in never-smokers, former
smokers, and current smokers for the two categories
(doctor-diagnosed COPD and chronic bronchitis) (see
Tables 4, 5 file). The sensitivity of the question “Have
you been diagnosed by a physician as having COPD oremphysema?” was higher in smokers, compared to never-
smokers (Table 4) (see Tables 4, 5 file).
Discussion
Diagnostic accuracy of the questionnaire
The question “Have you been diagnosed by a physician
as having COPD or emphysema?” is commonly used in
population-based epidemiological studies. In this general
population-based study, it scored low sensitivity (5.7%
for GOLD and 9.8% for LLN) and high specificity to de-
tect significant airflow obstruction according to GOLD
guidelines (99.7%) and ATS/ERS recommendations based
on LLN (99.5%), as well as a rather high LR + and a rea-
sonable PPV (63.6% and 48.5% for GOLD and LLN,
respectively). These results suggest that the question is
truly associated with COPD and prevents misclassifica-
tion of non-COPD subjects by spirometry. Unfortunately,
the low sensitivity implies that a significant number
of subjects with COPD cannot be identified by this
question, and reflects the well-known underdiagnosis of
COPD by physicians [18], even using the more stringent
LLN criteria [6]. However, in analytical epidemiological
studies, especially when the aim is to evaluate a risk fac-
tor, it is preferable to have a test/question with very high
specificity and lower sensitivity, to avoid false positive
findings and, consequently, bias in risk estimates [19].
Analyzing a subsample of subjects >40 years old, at which
age the disease is more likely to be diagnosed, did not sig-
nificantly change the results.
The accuracy of questionnaire items to identify COPD
has previously been criticized [20] and they will never
replace spirometry to make diagnosis [21]. Unsurpris-
ingly, the sensitivity in detecting COPD through asking
the question “Have you been diagnosed by a physician as
having COPD or emphysema?” is lower compared to
that of the question “Have you been diagnosed by a
physician as having asthma?” in defining true asthma
cases [8] because asthma is more widely known to pa-
tients and physicians. Recently, the accuracy of question-
naire items in defining COPD was assessed with the
main purpose of developing a screening tool for primary
care [11,22]; in these studies, a set of mixed questions
on symptoms and personal information achieved good
sensitivity and reasonable specificity. However, they in-
cluded only high risk groups (smokers), excluding those
with a self-reported doctor diagnosis of COPD, making
comparison impossible. In another study, female nurses
reporting a physician diagnosis of COPD were selected
to perform pulmonary function tests. The results showed
a slightly higher accuracy than seen in our population
[13]. This could possibly be explained by the sample se-
lection. Health care professionals, because of their educa-
tion, are probably more likely to correctly report their
medical history compared to non-health care professionals.
Table 2 Diagnostic accuracy of the question “Have you been diagnosed by a physician as having COPD or emphysema?”
and of self-reported, questionnaire-based chronic bronchitis symptoms to detect chronic obstructive pulmonary disease
(COPD)
FEV1/FVC <0.7 (GOLD) FEV1/FVC <1.645 SD below predicted (ATS/ERS)
Value 95% CI Value 95% CI
Physician-diagnosed COPD Sensitivity 0.057 0.027–0.088 0.098 0.04–0.156
Specificity 0.997 0.994–0.999 0.995 0.993–0.998
LR+ 16.859 6.894–41.228 21.532 9.226–50.25
PPV 0.636 0.427–0.846 0.485 0.267–0.702
NPV 0.911 0.899–0.922 0.962 0.954–0.97
Chronic bronchitis symptoms Sensitivity 0.046 0.019–0.074 0.074 0.022–0.125
Specificity 0.979 0.973–0.985 0.979 0.973–0.985
LR+ 2.244 1.161–4.337 3.520 1.664–7.443
PPV 0.189 0.086–0.292 0.133 0.044–0.223
NPV 0.908 0.896–0.920 0.960 0.952–0.968
ATS = American Thoracic Society; CI = confidence interval; ERS = European Respiratory Society; FEV1 = forced expiratory volume in 1 second; FEV1/FVC = FEV1/forced
vital capacity ratio; Gold = Global Initiative for Chronic Obstructive Lung Disease; LR + = positive likelihood ratio; NPV = negative predictive value; PPV = positive
predictive value; SD = standard deviation.
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identical medical history to receive a physician diagnosis of
COPD [23], women have a higher probability of having
COPD when reporting physician-diagnosed COPD, as also
shown in our data (Table 3). Not surprisingly, the question
about COPD was more accurate in indicating airwayTable 3 Diagnostic accuracy of the question “Have you been d
and of self-reported, questionnaire-based chronic bronchitis sy
(COPD) in men and women
FEV1/FVC <0
Value
















ATS = American Thoracic Society; CI = confidence interval; ERS = European Respirato
vital capacity ratio; Gold = Global Initiative for Chronic Obstructive Lung Disease; NPobstruction compared to the combination of questions that
defined chronic bronchitis (cough and phlegm for at least
3 months, 2 years consecutively). This suggests that sub-
jects other than persons with COPD (e.g., subjects with
asthma or repeated respiratory infections) also reported
these symptoms. In fact, subjects with chronic bronchitisiagnosed by a physician as having COPD or emphysema?”
mptoms to detect chronic obstructive pulmonary disease
.7 (GOLD) FEV1/FVC <1.645 SD below predicted (ATS/ERS)

















ry Society; FEV1 = forced expiratory volume in 1 second; FEV1/FVC = FEV1/forced
V = negative predictive value; PPV = positive predictive value.
Table 4 Diagnostic accuracy of the question “Have you been diagnosed by a physician as having COPD or emphysema?”
to detect chronic obstructive pulmonary disease (COPD), in non-smokers, ex-smokers, and current smokers
FEV1/FVC <0.7 (GOLD) FEV1/FVC <1.645 SD below predicted (ATS/ERS)
Value 95% CI Value 95% CI
Sensitivity Non-smokers 0.009 −0.014–0.032 0.022 −0.033–0.077
Ex-smokers 0.070 0.017–0.124 0.138 0.025–0.251
Current smokers 0.087 0.021–0.153 0.117 0.013–0.220
Specificity Non-smokers 1 1
Former smokers 0.992 0.986–0.998 0.991 0.985–0.997
Current smokers 0.996 0.989–1.003 0.991 0.981–1.000
PPV Non-smokers 1 1
Former smokers 0.5 0.22–0.78 0.4 0.126–0.674
Current smokers 0.833 0.564–1.102 0.583 0.228–0.939
NPV Non-smokers 0.941 0.928–0.955 0.976 0.967–0.985
Former smokers 0.906 0.886–0.925 0.964 0.951–0.976
Current smokers 0.830 0.792–0.867 0.914 0.886–0.942
ATS = American Thoracic Society; CI = confidence interval; ERS = European Respiratory Society; FEV1 = forced expiratory volume in 1 second; FEV1/FVC = FEV1/forced
vital capacity ratio; Gold = Global Initiative for Chronic Obstructive Lung Disease; NPV = negative predictive value; PPV = positive predictive value.
Murgia et al. BMC Pulmonary Medicine 2014, 14:49 Page 5 of 7
http://www.biomedcentral.com/1471-2466/14/49have a higher rate of respiratory infections (40%) compared
to subjects with COPD (33.1%) and the general population
(33.2%) (data not shown). Surprisingly, just 6.1% of the par-
ticipants with a history of physician-diagnosed COPD had
chronic bronchitis symptoms, suggesting that COPD could
be underdiagnosed or misdiagnosed. Given the high num-
ber of subjects with wheeze (24.6% using the GOLD defin-
ition and 31.3% with the LLN definition), we cannot
exclude that asthma was also underdiagnosed or underre-
ported in our population. However, wheezing is often also
associated with COPD [24] and the results did not changeTable 5 Diagnostic accuracy of self-reported, questionnaire-b
obstructive pulmonary disease (COPD), in non-smokers, ex-sm
FEV1/FVC <0.7 (GOLD)
Value 95% CI
Sensitivity Non-smokers 0.044 −0.004–0.09
Ex-smokers 0.042 0–0.084
Current smokers 0.052 0–0.104
Specificity Non-smokers 0.981 0.973–0.989
Former smokers 0.979 0.968–0.989
Current smokers 0.977 0.960–0.993
PPV Non-smokers 0.128 −0.006–0.26
Former smokers 0.182 0.014–0.35
Current smokers 0.333 0.056–0.611
NPV Non-smokers 0.943 0.929–0.956
Former smokers 0.901 0.881–0.921
Current smokers 0.821 0.783–0.86
ATS = American Thoracic Society; CI = confidence interval; ERS = European Respirato
vital capacity ratio; Gold = Global Initiative for Chronic Obstructive Lung Disease; NPsignificantly when the analysis was performed in the sub-
jects not reporting wheezing (data nor shown).
The accuracy of questionnaire questions in detect-
ing airflow obstruction did not differ between men and
women. The reported question on doctor-diagnosed COPD
showed higher sensitivity in detecting COPD in smokers
compared to non-smokers, whereas the PPV was higher
in current smokers than in non-smokers. Just one non-
smoker reported doctor-diagnosed COPD, but in non-
smokers there was no false positive result. This interaction
of smoking habits with the accuracy of the question isased chronic bronchitis symptoms to detect chronic
okers, and current smokers














ry Society; FEV1 = forced expiratory volume in 1 second; FEV1/FVC = FEV1/forced
V = negative predictive value; PPV = positive predictive value.
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underdiagnosis of COPD in primary care, where physi-
cians are more likely to make the diagnosis if the patient
is a smoker [25].
In the present study, chronic bronchitis symptoms
were fairly common in those who were excluded because
of reporting physician-diagnosed asthma (8.6%), higher
than in subjects with COPD according to either the
GOLD or the LLN definition (data not shown).
Validity issues
In this study, only pre-bronchodilator spirometric data
was available. Because the GOLD guidelines give a FEV1/
FVC ratio of <0.7 as cutoff point to diagnose COPD,
based on post-bronchodilator data, and the American
College of Chest Physicians, American College of Physi-
cians, ATS, and ERS define COPD as a disease character-
ized by an airflow obstruction not fully reversible [3], this
could be considered the main limitation of this study,
bearing to an overdiagnosis of COPD. Anyway, the
prevalence of COPD in our sample of the general popu-
lation was lower than expected, based on previous
studies [26,27], even if the FEV1/FVC ratio was derived
from pre-bronchodilator data. Nonetheless, in another,
similar study, a pre-bronchodilator FEV1/FVC ratio was
accepted [28] and at the time the present study was per-
formed the guideline of the UK National Institute for
Clinical Excellence did not consider spirometric revers-
ibility testing a necessary part of the diagnostic process
[29]. As a matter of fact, the bronchodilator response suf-
fers from a lack of reproducibility [30,31], being influ-
enced by smoking habits and other parameters [32],
and failed to discriminate between asthma and COPD
[31,33]. However is undeniable that pharmacological
bronchodilation with salbutamol would influence FEV1/
FVC ratio, increasing it in normal subjects and in pa-
tients with mild stages of COPD [34]. This expected
increase could affect sensitivity and other measures of
validity in this study. Unfortunately the variability of
post-bronchodilator response in FEV1/FVC found in
other studies [34,35] and the lack of data on post-
bronchodilator response in our study makes very difficult
to estimate this effect in our population.
The choice of using the European Community for
Steel and Coal (ECSC)/ERS equation [15] to calculate
LLN could be another limitation, since it will not take in
consideration the non-linear decline of FEV1 related to
the age. Nevertheless the aim of this study was to assess
the diagnostic accuracy of a questionnaire and, to make
our results comparable and applicable in clinical and
epidemiological practice, we had to rely on those methods
still most widely used, despite some relevant limitations.
The Finally, the subjects we excluded because they did
not respond to the questions regarding smoking couldhave biased our accuracy estimates. However, a further
analysis including these subjects confirmed our results
(data not shown).
Conclusions
This was the first study to assess the accuracy in detect-
ing COPD through a frequently used questionnaire item.
The high specificity and good PPV suggest that the ques-
tion “Have you been diagnosed by a physician as having
COPD or emphysema?” is more likely to identify those
who do not have the disease, whereas the low sensitivity
of this question could underestimate the real burden of
COPD in the general population.
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